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Introduction
Abacavir is a nucleoside reverse transcriptase inhibitor
(NRTI) used for treatment of HIV infection. HIV
infection is usually treated with antiretroviral therapy
regimens, which consist of three or more different drugs
used in combination. Typical antiretrovirals used in these
regimens include NRTIs, non-NRTIs, protease inhibi-
tors, and integrase strand inhibitors [1]. Abacavir makes
an ideal addition to these types of combination therapies
because of its dosing flexibility. It can be administered
either once or twice a day to match the dosing pattern of
other drugs and can also be administered as tablets that
contain other antiretroviral drugs such as lamivudine and
zidovudine, allowing for a reduction in pill count [2].
Abacavir is generally well tolerated, and common side
effects include nausea, headache, and diarrhea [2].
However, B5–8% of patients experience a hypersensi-
tivity reaction (HSR) within the first 6 weeks of treat-
ment. Symptoms of an HSR include at least two of the
following: fever, rash, cough, gastrointestinal symptoms,
dyspnea, and fatigue [3]. These symptoms worsen with
continued treatment, but typically improve within 24 h
after discontinuation. However, drug rechallenge after
discontinuation of abacavir because of an HSR can result
in symptom recurrence within a matter of hours, and can
lead to immediate and potentially fatal allergic reac-
tions [4,5]. This hypersensitivity reaction is strongly
linked to the presence of the HLA-B*57:01 allele, and
testing for the allele before abacavir treatment is
recommended by the US Food and Drug Administration
(FDA) [6], the European Medicines Agency [7], the
Clinical Pharmacogenetics Implementation Consortium
[3], and the Dutch Pharmacogenetics Working Group [8].
Abacavir was also reported to be associated with a higher
risk for myocardial infarction as compared with other
NRTIs [9–12]. However, a meta-analysis carried out
by the FDA in 2012 failed to find any such associa-
tion [13].
Drug interactions
As abacavir is primarily metabolized by cytosolic alcohol
dehydrogenase (ADH) and uridine diphosphate glucur-
onosyltransferase (UGT) enzymes, no interactions be-
tween abacavir and inducers or inhibitors of cytochrome
P450 (CYP) enzymes are predicted [2]. In addition, in-
vitro studies have shown that abacavir is unlikely to
inhibit CYP enzymes at clinically relevant concentra-
tions [14]. As non-NRTIs and protease inhibitors are
primarily metabolized by CYP enzymes [15], this may
eliminate the potential for drug interactions with
these types of antiretrovirals. No clinically significant
pharmacokinetic changes were seen when abacavir was
administered with other NRTIs such as lamivudine and
zidovudine [2,16]. As alcohol is also metabolized by
ADH, pharmacokinetic interactions between the drug
and ethanol have been analyzed, but no clinically
significant changes or new adverse events have been
reported [17]. Several studies have found a link between
abacavir administration and virologic response in hepatitis
C patients being treated with ribavirin and pegylated
interferon who are also coinfected with HIV; in these
patients, abacavir usage has been found to be significantly
associated with early virologic failure [18] and lack of
sustained virologic response [19,20]. However, subpopu-
lation analyses from two of the studies found that the
impact of abacavir on sustained virologic response was
only significant in patients with baseline hepatitis C viral
RNA above a certain level [20], ribavirin daily doses
below a certain level [20], or ribavirin trough concentra-
tions below a certain level [19]. In addition, a number of
studies have found no association between abacavir usage
and virologic response [21–24]; therefore, it is uncertain
whether these two drugs have a significant and harmful
interaction.
Pharmacokinetics
A schematic representation of abacavir disposition within
the body is provided in Fig. 1. Abacavir is rapidly absorbed
following oral administration, and has a mean absolute
bioavailability of B83% [2,25]. The drug is lipophilic
yet also shows high water solubility, allowing it to cross
cell membranes by passive diffusion alone. These proper-
ties may explain its high bioavailability, as well as
its ability to easily penetrate into tissues such as the
blood–brain barrier [2,26]. After absorption, abacavir is
extensively metabolized within the liver, with less than
2% of the drug excreted unchanged in the urine [27].
ADH and UGT are the primary enzymes responsible for
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abacavir metabolism within hepatocytes. Metabolism by
ADH results in the inactive carboxylate metabolite
2269W93; metabolism by the UGT enzymes results in
the inactive glucuronide metabolite 361W94 [27]. A mass
balance study found that 83% of the original dose was
eliminated in the urine and 16% in the feces. Of the 83%
eliminated through urine, 36% of the dose recovered was
the glucuronide metabolite, and 30% was the carboxylate
Fig. 1
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Schematic representation of abacavir pharmacokinetics and pharmacodynamics. The potential mechanism of an abacavir hypersensitivity
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metabolite. The remaining dose was either the parent
drug or trace metabolites [2,27].
The parent drug that is not metabolized by hepatocytes
undergoes metabolism within viral-infected cells by a
different set of intracellular enzymes, converting the drug
into its pharmacologically active metabolite. Initially,
abacavir is metabolized to abacavir 50-monophosphate by
the enzyme adenosine phosphotransferase (encoded by the
ADK gene). It then undergoes deamination by an unknown
cytosolic enzyme to form (–)-carbovir 50-monophosphate;
no diphosphates or triphosphates of abacavir have been
detected within cells [26,28]. (–)-Carbovir 50-monophos-
phate is then converted to (–)-carbovir 50-diphosphate by
the enzyme guanylate kinase (GUK1), which is stereo-
selective for the (–) enantiomer of carbovir [28–30]. One
study in particular found that (–)-carbovir 50-monophos-
phate was 7000 times more efficient as a substrate
for guanylate kinase than the (+) enantiomer [30].
(–)-Carbovir 50-diphosphate is then converted to the active
50-triphosphate form by various cellular kinases. These
include creatine kinases (represented by the CK gene
group in Fig. 1), pyruvate kinases (PK gene group),
nucleoside diphosphate kinases (NME gene group),
phosphoglycerate kinase (PGK1), and phosphoenolpyruvate
carboxykinase (PCK1). Given the stereoselectivity of
guanylate kinase, only (–)-carbovir 50-triphosphate (CBV-
TP) is formed in any significant quantity. However, the (+)
enantiomer has equivalent antiviral activity [28,30].
Abacavir can also be converted to carbovir 50-monophos-
phate by other minor pathways, such as transformation
into carbovir, followed by phosphorylation of carbovir into
carbovir 50-monophosphate by inosine phosphotransfer-
ase. As these pathways make up less than 2% of abacavir
metabolism, they are not shown in Fig. 1 [28].
Pharmacodynamics
A stylized depiction of the mechanism of action of
abacavir within host cells is provided in Fig. 1. CBV-TP
represents the active form of abacavir and works by
blocking the action of HIV reverse transcriptase (HIV-
RT). HIV replicates by taking advantage of the host cell’s
existing genetic machinery, as well as using the viral
enzyme reverse transcriptase, which is responsible for the
conversion of viral RNA into double-stranded DNA. The
viral DNA can then be incorporated into the host DNA,
at which point the host machinery may convert the
DNA into viral RNA. The viral RNA is then translated
into viral proteins, which assemble to form the HIV
virus [31]. CBV-TP acts as a guanosine analog, and
competes for incorporation into the nucleotide chain
being produced by HIV-RT from the viral RNA [26].
Other NRTIs can act as derivatives of different nucleo-
sides, leading to the same type of inhibition. Examples
of this are didanosine and adenosine, zalcitabine and
cytidine, and zidovudine and thymidine [32]. After
incorporation of CBV-TP into the nucleotide chain, its
lack of a 30-OH on the deoxyribose sugar on which
subsequent nucleotides are added blocks continuing
synthesis of viral DNA [28,31]. A comparison between
the structures of carbovir triphosphate and deoxyguano-
sine triphosphate, as well as the structure of abacavir, is
shown in Fig. 2.
CBV-TP is particularly well suited for this role as it is
highly selective for reverse transcriptase as compared
with DNA polymerases a, b, g, and E. Indeed, Ki values
for DNA polymerases a, b, g, and E were 90-, 2900-,
1200-, and 1900-fold greater, respectively, than the
Ki value for HIV-RT [26]. This selectivity for reverse
transcriptase prevents the potentially toxic side effects
that occur when DNA polymerases are inhibited. Many
antiretroviral NRTIs are associated with a range of
adverse events attributed to mitochondrial dysfunction,
such as lactic acidosis and hepatic steatosis. These are
believed to result from the inhibition of mitochondrial
DNA polymerase g by these drugs, leading to altered
mitochondrial DNA replication and resulting in mito-
chondrial myopathy and toxicity. Abacavir has the lowest
inhibition rate for DNA polymerase g, whereas zalcita-
bine, didanosine, and stavudine have the highest [32].
Pharmacogenetics
The pharmacogenetics of abacavir is well established and
is almost exclusively related to the human leukocyte
antigen B (HLA-B) gene and its variant allele *57:01. This
particular allele has been shown to be strongly associated
with abacavir HSR in a large number of studies, as
discussed below. However, the positive predictive value
for this allele is below 50% [33], indicating that additional
factors, genetic or otherwise, may be involved in the
development of an HSR. Limited research has been
conducted in this area, although some potential exists for
a variant in the gene HSP70-HOM (also known as
HSP1AL), whose protein is hypothesized to be directly
involved in the stimulation of an immune reaction to
abacavir [34].
HLA-B*57:01
The HLA-B gene is a member of the major histocompat-
ibility complex region located on chromosome 6. This
genomic region encodes three groups of genes involved in
the immune system. HLA-B is part of the class I group,
along with HLA-A and HLA-C, all of which code for their
eponymous proteins. The HLA-B protein and the other
class I group members are cell-surface molecules
responsible for the presentation of endogenous peptides
to immune system cells and exist on almost all nucleated
cells. This is in contrast to class II molecules, which
display exogenous peptides and are present only on
antigen presenting cells such as macrophages or dendritic
cells. Briefly, class I molecules such as HLA-B are
heterodimers consisting of an a-chain, encoded by the
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HLA-B gene, and a protein known as b2-microglobulin,
which is encoded on chromosome 15. The a-chain of
HLA-B has four domains: one cytoplasmic, one trans-
membrane, one that binds to CD8+ cytotoxic T cells,
and the last that makes up a peptide-binding groove, in
which the peptide to be presented is nestled. The region
of the gene encoding the peptide-binding groove is highly
polymorphic, allowing for the presentation of a wide
variety of peptides. Most of the peptides that HLA-B
presents come from the normal breakdown of cellular
proteins and are recognized by the immune system as
such (i.e. ‘self ’ peptides). However, when a cell becomes
infected by a pathogen, the proteins presented will be
from the pathogen and recognized as foreign or ‘non-self ’.
T-cell antigen receptors on CD8+ cytotoxic T cells are
responsible for this recognition and stimulate an immune
reaction and destroy the cell [35,36].
In 2002, two separate research groups published evidence
that an allele known as HLA-B*57:01 was present in a
significantly higher percentage of patients showing an
abacavir HSR compared with patients with no reaction.
One study was conducted on a North American popula-
tion [37] and the other on a population known as the
Western Australian HIV cohort [4]. Both included 200
patients. This was confirmed by another study that
included 64 participants from the UK [38]. However,
these three studies were conducted predominantly on
White males, limiting their scope. Despite this limitation,
several clinics began implementing prospective screening
for these alleles to great success [39–41]. A later study
recognized the significance of this allele in White female
and Hispanic populations, but did not find any significant
associations in Black populations [42]. This was likely
because of the lower number of Black patients within this
study (as compared with Hispanics and Whites) and the
fact that Black populations have a lower carriage rate of
the allele [42,43]. European populations have a *57:01
allele frequency of about 6–7%, but African populations
often have allele frequencies of less than 2.5%. In
addition, some Asian populations, such as the Japanese
or South Koreans, have extremely low allele frequencies
of 0.5% or less; in contrast, some Indian populations have
*57:01 frequencies of greater than 16% [3] (allele
frequency information taken from the supplementary
information). In 2007, a study known as SHAPE (which
included a similar number of White and Black partici-
pants) found that Black patients did have fewer cases of
abacavir HSRs. However, in patients with immuno-
logically confirmed HSRs, 100% of both White and Black
patients were positive for the HLA-B*57:01 allele. This
suggested that, although immunologically confirmed
HSRs are rare among Black populations because of the
reduced carriage of the allele, HLA-B*57:01 has the same
clinical implications in both populations [44]. A definitive
association between this allele and abacavir HSRs came
in 2008 with the results of the PREDICT-1 study, a
double-blind, prospective, randomized study with 1956
patients from 19 countries. Patients were observed for 6
weeks and separated into two categories: those who
underwent screening for the HLA-B*57:01 allele and were
eliminated if they tested positive, and those who
underwent standard care without any screening. Abacavir
HSRs were immunologically confirmed by skin patch
testing. The results of the study showed that screening
completely eliminated HSRs – 0% of the patients
screened had an HSR, whereas 2.7% of the control
population had an HSR. This gave screening a negative
predictive value of 100%. However, the study had a
positive predictive value of 47.9%, indicating that about
half of all the patients who are HLA-B*57:01 positive will
not develop an abacavir HSR [33]. This indicates that
additional factors, genetic or nongenetic, are likely
involved in the development of an HSR. This paper,
along with the large amount of other existing evidence,
led the FDA to implement a boxed warning in 2008,
detailing the risk for HSRs in abacavir-treated patients
with the HLA-B*57:01 allele [6]. The FDA [6], along
with the European Medicines Agency [7], Clinical
Pharmacogenetics Implementation Consortium [3], and
Dutch Pharmacogenetics Working Group [8], also re-
commend that all patients be screened before being
treated and that abacavir not be used in HLA-B*57:01-
positive individuals.
The HLA-B protein has no direct effect on abacavir
pharmacokinetics or pharmacodynamics, and it is still
Fig. 2
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unclear how the HLA-B*57:01 allele affects susceptibility
to drug hypersensitivity. Several hypotheses exist. One
theory is the hapten concept, which suggests that small
compounds such as drugs (called ‘haptens’) bind to the
peptides bound to immune receptors such as HLA-B,
causing T cells to react and stimulate an immune
reaction [45]. Another theory is the p-i concept
(pharmacological interactions with immune receptors),
which suggests that drugs bind directly and reversibly to
immune receptors, stimulating an immune reaction [45].
Recent evidence seems to support an alternative
hypothesis. Two studies, both published in 2012, found
that abacavir can bind noncovalently and with specificity
to the F pocket of the peptide-binding groove of HLA-
B*57:01 [46,47]. Because of the amino acid residues
unique to the *57:01 allele, abacavir can bind only to this
particular form of HLA-B. The binding of abacavir to
HLA-B*57:01 is believed to change the shape and
chemistry of the antigen-binding cleft, and consequently
the repertoire of peptides that can bind the molecule.
Indeed, both of these papers, as well as an additional
paper by Norcross and colleagues, identified particular
changes in the peptides presented by HLA-B*57:01 in
the presence of abacavir, as compared with those when
the drug was absent [46–48]. Conventional HLA-B*57:01
epitopes frequently possess large hydrophobic amino
acids such as tryptophan or phenylalanine at their
C-terminus; however, Illing and colleagues [46–48] found
that peptides eluted in the presence of abacavir showed a
preference for isoleucine or leucine at this position. This
binding and subsequent peptide alteration is shown in
the pathway figure – a dashed line is used, as this
mechanism is not currently well established. The typical
cycle of peptide loading and transport to the cell-surface
plasma membrane [49] is also shown. As T cells are
trained to be tolerant to a particular repertoire of
peptides during their development in the thymus, an
alteration in the peptides that are presented may mean
that these new peptides are perceived as foreign. This
change would stimulate CD8+ T-cell production and
response, and would manifest as an abacavir HSR [46,47].
Indeed, CD8+ T cells are abundant in skin biopsies of
patients who present with a rash during an abacavir
HSR [50].
HSP70-HOM
The positive predictive value of B50% for the
HLA-B*57:01 allele and abacavir HSRs indicates the
need for further studies to elucidate whether other genes
affect the development of an HSR. Research in this area
has been scarce, but several studies have suggested a
member of the 70 kDa heat shock protein (HSP70)
family to be a potential factor. The HSP70 proteins are
responsible for protecting cells from stress, as well as
assist in other cellular activities, such as protein folding
[51]. Three genes within the human major histocompat-
ibility complex region encode members of the HSP70
family: HSP70-1, HSP70-2, and HSP70-HOM [52].
HSP70-1 and HSP70-2 encode identical heat-inducible
protein products, whereas HSP70-HOM (also known as
HSP1AL) encodes a similar but non-heat-inducible
protein [52]. A study using the Western Australian HIV
cohort found that the reference C allele at rs2227956 in
the HSP70-HOM gene (which results in a threonine at
residue 493 as opposed to a methionine) was found in
combination with the HLA-B*57:01 allele in 94.4% of
immunologically confirmed hypersensitive cases and 0.4%
of controls, whereas the HLA-B*57:01 allele appeared on
its own in 94.4% of hypersensitive cases and 1.7% of
controls. The authors suggested that consideration of the
HSP70-HOM allele in addition to the HLA-B*57:01 allele
may therefore increase the ability to discriminate between
patients who would develop an HSR and tolerant controls.
The population consisted of 230 controls and 18 patients
with an HSR, and the alleles were found to be in strong
linkage disequilibrium [53]. Further studies in larger
populations are needed to verify this association. How-
ever, a later study did find that the HSP70-HOM protein
colocalized with both the HLA-B*57:01 protein and
abacavir within the endoplasmic reticulum. This implies
that the HSP70-HOM 493T variant may lead to a protein
that somehow facilitates the presentation of abacavir
antigens to CD8+ T cells, perhaps by chaperoning the
drug in antigen processing [34].
Conclusion
The implementation of HLA-B*57:01 testing before
abacavir treatment is one of the best examples of
pharmacogenetic research being used in the clinic.
Genotyping for this allele is widely available in the
western world. Despite this, further research should still
be conducted on additional factors that lead to a
propensity for an abacavir HSR. This could increase the
positive predictive value, allowing more patients to be
administered abacavir who could benefit from treatment.
Currently there is very little evidence for the involve-
ment of other genes, and only HSP70-HOM has emerged
as a potential factor. Further advancement of our under-
standing in this area could prevent inappropriate denial of
abacavir to patients who would tolerate it and hopefully
help further elucidate the mechanism by which abacavir
elicits its hypersensitivity reaction.
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